Andrew Combs - 25 Mar 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Chief Chemistry Officer
Issuer ticker: PRLD
Reported as of: 25 Mar 2025
Net transaction value: +$69,250
SEC form: 4
Accepted by SEC: 27 Mar 2025, 16:40:54 UTC
Prior SEC filing: 05 Feb 2025
Next SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Krishna Vaddi, Attorney-in-Fact

Key filing fact

Andrew Combs filed Form 4 for Prelude Therapeutics Inc (PRLD) on 27 Mar 2025.

Key facts

This page summarizes Andrew Combs's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Mar 2025, 16:40.

Change

Previous filing in this sequence was filed on 05 Feb 2025.
Current net transaction value: +$69,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRLD transaction

Common Stock

Purchase

Transaction value: $69,250
Shares: +100,000
Change %: +26%
Price: $0.6925
Shares after: 480,123
Date: 25 Mar 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).